Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia-Reference-Cited by-同舟云学术

Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia

Published:2024-09-05 Issue: Volume: Page:
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Wang Jianxiang^ORCID,Jiang Bin,Li Jian^ORCID,Liu Ligen,Du Xin,Jiang Hao,Hu Jianda^ORCID,Yuan Menghe,Sakatani Taishi^ORCID,Kadokura Takeshi,Takeuchi Masato,Kosako Masanori^ORCID,Ma Xiao,Girshova Larisa^ORCID,Tan Jerome,Bondarenko Sergey,Lee Lily Wong Lee,Khuhapinant Archrob,Martynova Elena,Hasabou Nahla

Funder

Astellas Pharma US

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02382-9.pdf

Reference27 articles.

1. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117:3294–301.

2. Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M, et al. A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia. 2011;25:939–44.

3. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299–312.

4. Moreno I, Martin G, Bolufer P, Barragan E, Rueda E, Roman J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88:19–24.

5. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776–84.